Strides Pharma Science Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023-04 to 2024-03🗂️ Report periods on file: 2023-04 to 2024-03, 2022-04 to 2023-03, 2020-21

In its 2023-04 to 2024-03 reporting, Strides Pharma Science Limited disclosed greenhouse gas emissions of 25.9K tCO2e/year (Scope 1 & 2 combined). By scope: Scope 1: 5.3K tCO2e/year; Scope 2: 19.9K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
25.9K tCO2e/year (Scope 1 & 2 combined)
2023-04 to 2024-03
⚡
Renewable Energy
~44% of total energy use
of total energy
💧
Water Usage
204.4K m3/year
2023-04 to 2024-03
♻️
Waste
826 tons/year
2023-04 to 2024-03
⚙️
Energy Use
53.4M Kwh/year
2023-04 to 2024-03

📊 Emissions by Scope (2023-04 to 2024-03)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).5.3K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.19.9K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2023-04 to 2024-0325.9K tCO2e/year (Scope 1 & 2 combined)
2022-04 to 2023-0325.6K tCO2e/year (Scope 1 & 2)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Increase clean energy consumption to 50% by FY25
  • Reduce carbon footprint by 45% by FY25
  • Increase water recycling to 45% by FY25

📅 Medium-term

  • Increase share of women in total permanent workforce to 25% by FY30
  • Ensure 50 hours of training per FTE on average by FY27
  • Third party audit of risk management processes- in line with ISO 31000 by FY27

🌱 ESG Focus Areas

Environmental SustainabilitySocial ImpactResponsible Governance

⚠️ Challenges & Risks +

  • Under-performance of international stressed assets resulting in impairment risk
  • Inability to achieve intended strategic M&A outcomes within the timelines envisaged resulting in loss of shareholder value
  • Cyber-attacks could lead to loss of confidentiality, data, information and loss of reputation
  • Non-fulfillment of contractual obligations resulting in financial and reputation loss
  • Critical inspection observations related to facilities/systems/deployment could culminate into regulatory action disrupting supply and delaying product approval
  • Product liability claims and potential recalls arising from nitrosamine related impurities
  • Impact on Environment and Society and related impact on operations
  • Emergence of Artificial Intelligence (AI) based technologies, with integration across pharma operations, accompanying challenges and adverse outcomes.
  • Escalating Geopolitical Tensions and Societal Unrest leading to significant operational disruptions across the supply chain, increasing costs, thereby impacting profitability.
  • Attracting and retaining skilled talent in the workforce, while addressing talent shortages in the pharmaceutical industry

📋 Report Information

Reporting Period: 2023-04 to 2024-03
Frameworks: GRI Standards 2021, UN Sustainable Development Goals (SDGs), SASB standards, BRSR disclosures